MXCT
MXCT
NASDAQ · Life Sciences Tools & Services

Maxcyte Inc

$1.08
+0.04 (+3.85%)
Financial Highlights (FY 2026)
Revenue
34.21M
Net Income
-46,224,356
Gross Margin
81.2%
Profit Margin
-135.1%
Rev Growth
-9.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 81.2% 81.2% 41.4% 41.4%
Operating Margin -157.1% -141.4% 7.9% 8.9%
Profit Margin -135.1% -128.4% 7.9% 6.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 34.21M 37.72M 11.59M 9.98M
Gross Profit 27.76M 30.61M 4.80M 4.13M
Operating Income -53,754,463 -53,339,599 910.9K 885.5K
Net Income -46,224,356 -45,867,607 913.3K 656.0K
Gross Margin 81.2% 81.2% 41.4% 41.4%
Operating Margin -157.1% -141.4% 7.9% 8.9%
Profit Margin -135.1% -128.4% 7.9% 6.6%
Rev Growth -9.3% -9.3% +8.1% +21.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 17.20M 19.69M
Total Equity 38.88M 41.65M
D/E Ratio 0.44 0.47
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -49,377,270 -51,718,199 1.25M 1.22M
Free Cash Flow 402.0K 324.3K